Top

Breast Cancer Research and Treatment

Published in:

01-04-2017 | Epidemiology

Sleep duration and breast cancer prognosis: perspectives from the Women’s Healthy Eating and Living Study

Authors: Catherine R. Marinac, Sandahl H. Nelson, Shirley W. Flatt, Loki Natarajan, John P. Pierce, Ruth E. Patterson

Published in: Breast Cancer Research and Treatment | Issue 3/2017

Abstract

Purpose

To examine whether baseline sleep duration or changes in sleep duration are associated with breast cancer prognosis among early-stage breast cancer survivors in the multi-center Women’s Healthy Eating and Living Study.

Methods

Data were collected from 1995 to 2010. Analysis included 3047 women. Sleep duration was self-reported at baseline and follow-up intervals. Cox proportional hazard models were used to investigate whether baseline sleep duration was associated with breast cancer recurrence, breast cancer-specific mortality, and all-cause mortality. Time-varying models investigated whether changes in sleep duration were associated with breast cancer prognosis.

Results

Compared to women who slept 7–8 h/night at baseline, sleeping ≥9 h/night was associated with a 48% increased risk of breast cancer recurrence (Hazard ratio [HR] 1.48, 95% Confidence interval [CI] 1.01, 2.00), a 52% increased risk of breast cancer-specific mortality (HR 1.52, 95% CI 1.09, 2.13), and a 43% greater risk of all-cause mortality (HR 1.43, 95% CI 1.07, 1.92). Time-varying models showed analogous increased risk in those who inconsistently slept ≥9 h/night (all P < 0.05), but not in those who consistently slept ≥9 h/night.

Conclusions

Consistent long or short sleep, which may reflect inter-individual variability in the need for sleep, does not appear to influence prognosis among early-stage breast cancer survivors.

Howlander N, Noone A, Krapacho M, Miller D, Boship K, Alterkruse SF, C.L. K, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, E.J. F, Cronin KA SEER Cancer Statistics Revier, 1975–2013, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2013/. Based on November 2015 SEER data submission, posted to the SEER web site, April 2016

Bower JE (2008) Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol 26(5):768–777. doi:10.1200/JCO.2007.14.3248 PubMedPubMedCentralCrossRef

Alfano CM, Lichstein KL, Vander Wal GS, Smith AW, Reeve BB, McTiernan A, Bernstein L, Baumgartner KB, Ballard-Barbash R (2011) Sleep duration change across breast cancer survivorship: associations with symptoms and health-related quality of life. Breast Cancer Res Treat 130(1):243–254. doi:10.1007/s10549-011-1530-2 PubMedPubMedCentralCrossRef

Tamakoshi A, Ohno Y, Group JS (2004) Self-reported sleep duration as a predictor of all-cause mortality: results from the JACC study, Japan. Sleep 27(1):51–54PubMed

Patel SR, Ayas NT, Malhotra MR, White DP, Schernhammer ES, Speizer FE, Stampfer MJ, Hu FB (2004) A prospective study of sleep duration and mortality risk in women. Sleep 27(3):440–444PubMed

Hublin C, Partinen M, Koskenvuo M, Kaprio J (2007) Sleep and mortality: a population-based 22-year follow-up study. Sleep 30(10):1245–1253PubMedPubMedCentralCrossRef

Spiegel K, Leproult R, Van Cauter E (1999) Impact of sleep debt on metabolic and endocrine function. Lancet 354(9188):1435–1439. doi:10.1016/S0140-6736(99)01376-8 PubMedCrossRef

Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Follett H, Kales A, Chrousos GP (2004) Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 89(5):2119–2126. doi:10.1210/jc.2003-031562 PubMedCrossRef

Meier-Ewert HK, Ridker PM, Rifai N, Regan MM, Price NJ, Dinges DF, Mullington JM (2004) Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 43(4):678–683. doi:10.1016/j.jacc.2003.07.050 PubMedCrossRef

10.

Morris CJ, Aeschbach D, Scheer FA (2012) Circadian system, sleep and endocrinology. Mol Cell Endocrinol 349(1):91–104. doi:10.1016/j.mce.2011.09.003 PubMedCrossRef

11.

Schernhammer ES, Kroenke CH, Laden F, Hankinson SE (2006) Night work and risk of breast cancer. Epidemiology 17(1):108–111PubMedCrossRef

12.

Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES (2005) Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer 41(13):2023–2032. doi:10.1016/j.ejca.2005.05.010 PubMedCrossRef

13.

Vijayalaxmi Thomas CR Jr, Reiter RJ, Herman TS (2002) Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20(10):2575–2601. doi:10.1200/JCO.2002.11.004 PubMedCrossRef

14.

Dimitrov S, Lange T, Nohroudi K, Born J (2007) Number and function of circulating human antigen presenting cells regulated by sleep. Sleep 30(4):401–411PubMedCrossRef

15.

Phipps AI, Bhatti P, Neuhouser ML, Chen C, Crane TE, Kroenke CH, Ochs-Balcom H, Rissling M, Snively BM, Stefanick ML, Treggiari MM, Watson NF (2016) Pre-diagnostic sleep duration and sleep quality in relation to subsequent cancer survival. J Clin Sleep Med 12(4):495–503. doi:10.5664/jcsm.5674 PubMedPubMedCentralCrossRef

16.

Costa AR, Fontes F, Pereira S, Goncalves M, Azevedo A, Lunet N (2014) Impact of breast cancer treatments on sleep disturbances—a systematic review. Breast 23(6):697–709. doi:10.1016/j.breast.2014.09.003 PubMedCrossRef

17.

Savard J, Davidson JR, Ivers H, Quesnel C, Rioux D, Dupere V, Lasnier M, Simard S, Morin CM (2004) The association between nocturnal hot flashes and sleep in breast cancer survivors. J Pain Symptom Manag 27(6):513–522. doi:10.1016/j.jpainsymman.2003.10.013 CrossRef

18.

Palesh O, Aldridge-Gerry A, Zeitzer JM, Koopman C, Neri E, Giese-Davis J, Jo B, Kraemer H, Nouriani B, Spiegel D (2014) Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep 37(5):837–842. doi:10.5665/sleep.3642 PubMedPubMedCentral

19.

Hahm BJ, Jo B, Dhabhar FS, Palesh O, Aldridge-Gerry A, Bajestan SN, Neri E, Nouriani B, Spiegel D, Zeitzer JM (2014) Bedtime misalignment and progression of breast cancer. Chronobiol Int 31(2):214–221. doi:10.3109/07420528.2013.842575 PubMedCrossRef

20.

Pierce JP, Faerber S, Wright FA, Rock CL, Newman V, Flatt SW, Kealey S, Jones VE, Caan BJ, Gold EB, Haan M, Hollenbach KA, Jones L, Marshall JR, Ritenbaugh C, Stefanick ML, Thomson C, Wasserman L, Natarajan L, Thomas RG, Gilpin EA, Women’s Healthy E, Living study g (2002) A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women’s Healthy Eating and Living (WHEL) Study. Control Clin Trials 23(6):728–756PubMedCrossRef

21.

Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, Al-Delaimy WK, Bardwell WA, Carlson RW, Emond JA, Faerber S, Gold EB, Hajek RA, Hollenbach K, Jones LA, Karanja N, Madlensky L, Marshall J, Newman VA, Ritenbaugh C, Thomson CA, Wasserman L, Stefanick ML (2007) Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial. JAMA 298(3):289–298. doi:10.1001/jama.298.3.289 PubMedPubMedCentralCrossRef

22.

Levine DW, Kaplan RM, Kripke DF, Bowen DJ, Naughton MJ, Shumaker SA (2003) Factor structure and measurement invariance of the Women’s Health Initiative Insomnia Rating Scale. Psychol Assess 15(2):123–136PubMedCrossRef

23.

Levine DW, Kripke DF, Kaplan RM, Lewis MA, Naughton MJ, Bowen DJ, Shumaker SA (2003) Reliability and validity of the Women’s Health Initiative Insomnia Rating Scale. Psychol Assess 15(2):137–148PubMedCrossRef

24.

Levine DW, Dailey ME, Rockhill B, Tipping D, Naughton MJ, Shumaker SA (2005) Validation of the Women’s Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial. Psychosom Med 67(1):98–104. doi:10.1097/01.psy.0000151743.58067.f0 PubMedCrossRef

25.

Patterson RE, Flatt SW, Saquib N, Rock CL, Caan BJ, Parker BA, Laughlin GA, Erickson K, Thomson CA, Bardwell WA, Hajek RA, Pierce JP (2010) Medical comorbidities predict mortality in women with a history of early stage breast cancer. Breast Cancer Res Treat 122(3):859–865. doi:10.1007/s10549-010-0732-3 PubMedPubMedCentralCrossRef

26.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef

27.

Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483PubMedCrossRef

28.

Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA (2003) Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock. J Natl Cancer Inst 95(4):263–281PubMedCrossRef

29.

Kosinski M, Keller SD, Hatoum HT, Kong SX, Ware JE, Jr (1999) The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability. Medical care 37(5 Suppl):MS10–MS22PubMed

30.

Ware JE Jr, Gandek B (1998) Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. J Clin Epidemiol 51(11):903–912PubMedCrossRef

31.

Hirshkowitz M, Whiton K, Albert SM, Alessi C, Bruni O, DonCarlos L, Hazen N, Herman J, Hillard PJA, Katz ES, Kheirandish-Gozal L, Neubauer DN, O’Donnell AE, Ohayon M, Peever J, Rawding R, Sachdeva RC, Setters B, Vitiello MV, Ware JC (2015) National sleep foundation’s updated sleep duration recommendations: final report. Sleep Health 1(14):233–243. doi:10.1016/j.sleh.2015.10.004 CrossRef

32.

Anderson PK, Gill RD (1982) Cox’s regression model for counting processes: a large sample study. Ann Stat 10(4):1100–1120. doi:10.1214/aos/1176345976 CrossRef

33.

Tucker AM, Dinges DF, Van Dongen HP (2007) Trait interindividual differences in the sleep physiology of healthy young adults. J Sleep Res 16(2):170–180. doi:10.1111/j.1365-2869.2007.00594.x PubMedCrossRef

34.

Aeschbach D, Sher L, Postolache TT, Matthews JR, Jackson MA, Wehr TA (2003) A longer biological night in long sleepers than in short sleepers. J Clin Endocrinol Metab 88(1):26–30. doi:10.1210/jc.2002-020827 PubMedCrossRef

35.

Clinton JM, Davis CJ, Zielinski MR, Jewett KA, Krueger JM (2011) Biochemical regulation of sleep and sleep biomarkers. J Clin Sleep Med 7(5 Suppl):S38–S42. doi:10.5664/JCSM.1360 PubMedPubMedCentral

36.

Krueger JM (2008) The role of cytokines in sleep regulation. Curr Pharm Des 14(32):3408–3416PubMedPubMedCentralCrossRef

37.

Krueger JM, Takahashi ST, Kapas L, Bredow S, Roky R, Fang J, Floyd R, Renegar KB, Guha-Thakurta N, Novitsky S, Obar FJ (1995) Cytokines in sleep regulation. Adv Neuroimmunol 5:171–188PubMedCrossRef

38.

Villasenor A, Flatt SW, Marinac C, Natarajan L, Pierce JP, Patterson RE (2014) Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study. Cancer Epidemiol Biomark Prev 23(1):189–199. doi:10.1158/1055-9965.EPI-13-0852 CrossRef

39.

Reynold AM, Bowles ER, Saxena A, Fayad R, Youngstedt SD (2014) Negative Effects of Time in Bed Extension: a Pilot Study. J Sleep Med Disord 1(1):1

40.

Bardwell WA, Natarajan L, Dimsdale JE, Rock CL, Mortimer JE, Hollenbach K, Pierce JP (2006) Objective cancer-related variables are not associated with depressive symptoms in women treated for early-stage breast cancer. J Clin Oncol 24(16):2420–2427. doi:10.1200/JCO.2005.02.0081 PubMedCrossRef

41.

Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D (2011) Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol 29(4):413–420. doi:10.1200/JCO.2010.28.4455 PubMedCrossRef

42.

Suppli NP, Johansen C, Kessing LV, Toender A, Kroman N, Ewertz M, Dalton SO (2016) Survival after early-stage breast cancer of women previously treated for depression: a nationwide Danish cohort study. J Clin Oncol. doi:10.1200/JCO.2016.68.8358 PubMed

43.

Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS, Nemeroff CB (2001) Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 158(8):1252–1257. doi:10.1176/appi.ajp.158.8.1252 PubMedCrossRef

44.

Sephton SE, Dhabhar FS, Keuroghlian AS, Giese-Davis J, McEwen BS, Ionan AC, Spiegel D (2009) Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav Immun 23(8):1148–1155. doi:10.1016/j.bbi.2009.07.007 PubMedCrossRef

Title: Sleep duration and breast cancer prognosis: perspectives from the Women’s Healthy Eating and Living Study
Authors: Catherine R. Marinac
Sandahl H. Nelson
Shirley W. Flatt
Loki Natarajan
John P. Pierce
Ruth E. Patterson
Publication date: 01-04-2017
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4140-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2017

Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients

Plasma carotenoids and the risk of premalignant breast disease in women aged 50 and younger: a nested case–control study

Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials

Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study

A high frequency of PALB2 mutations in Jamaican patients with breast cancer

PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer